1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • August 2016
  • 416 pages
  • ID: 2466876
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

Summary
Coronary artery disease (CAD), which precipitates acute coronary syndrome (ACS), is the most common type of cardiovascular disease (CVD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). At present, the cardiovascular (CV) drug market is well established and boasts a multitude of branded and generic drug choices to treat the major conditions associated with ACS: thrombosis (fibrinolytics, anticoagulants, and antiplatelets), hypercholesterolemia/atherosclerosis (statins and PCSK9 inhibitors), and hypertension (renin angiotensin aldosterone system (RAAS) inhibitors and beta blockers). Due to this range of sub-indications and the recent increase in disease prevalence, it is evident that ACS represents a potentially lucrative market for Big Pharma to explore.

It is estimated that sales of acute coronary syndrome (ACS) therapeutics to be approximately $7.8B across the 7MM in 2015, including the US, the five major European markets (5EU: France, Germany, Italy, Spain, and UK), and Japan. In the 2015 base year 10% of market share were attributed to the acute phase sales ($714M) and 90% to the chronic phase ($7.0B). By 2025, the ACS market to grow at a strong Compound Annual Growth Rate (CAGR) of 4.6%, reaching sales of $12.1B by the end of the forecast period. This is mainly attributed to the chronic phase growth, which is forecast to reflect a CAGR of 5.0%, reaching $11.4B in sales by 2025 (94% of market share).

As per Michela J. McMullan, Analyst: “At present, a large proportion of patients with clinical atherosclerotic cardiovascular disease cannot reach guideline recommended levels of LDL-C with the standard of care therapies, which leads to recurrent ACS events.

Major drivers of ACS market growth over the forecast period are the -
- Launches of the first PCSK9 inhibitors, Repatha (evolocumab) and Praluent (alirocumab), in the US (2015), EU (2015), and Japan (2016); and positive results from their cardiovascular (CV) outcomes trials.
- Launch of first-in-class lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor/ adenosine monophosphate-activated protein kinase (AMPK) activator, ETC-1002, in 2021.
- Increase in the global prevalence of ACS.

The report “PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025” provides overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In depth, this report provides the following analysis -
- Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Amgen, AstraZeneca, Bristol-Myers Squibb, Cerenis Therapeutics, CSL Limited, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, Janssen Pharmaceuticals, (Johnson & Johnson), The Medicines Company, Merck, Pfizer, Sanofi

Highlights
Key Questions Answered
- The new generation antiplatelets, Brilinta and Effient will see a significant increase in patient shares for the treatment ACS against the previous cornerstone, clopidogrel. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the ACS market?
- The PCSK9 inhibitors recently launched into the CV market, and these are predicted to have a notable impact in the ACS space once their CV outcomes data is shown. The most notable candidate in the current late-stage ACS pipeline is ETC-1002, which is vying to target the needed statin intolerant ACS population. Will these newly marketed and late-stage drugs make a significant impact on the ACS market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- We have seen a notable increase in the ACS population in terms of diagnosed prevalent ACS cases , as well as ACS hospitalisations (incidence and recurrent events). How will epidemiological changes impact the growth of the future market?

Key Findings
- The main driver of the significant expansion of the ACS market will be the increase in use and physician confidence in the PCSK9 inhibitor class, which will hold four major players by the end of this forecast. Novel lipid lowering therapy, ETC-1002, will also be a major contributor, vying to steal majority of patient shares for the statin intolerant ACS population by the end of this forecast.
- The major global barrier for the ACS market will be the generic erosion of the key antiplatelet therapies, Brilinta and Effient by the end of this forecast. Both drugs will pick up significant momentum in sales prior to patent expiry.
- The dynamics of the ACS market will shift greatly towards solving the atherosclerotic burden associated in ACS from the historical strategy of developing antithrombotic therapies.
- The key market opportunities lie in addressing unmet needs through the development of optimal agents for secondary prevention by controlling lipid levels and repairing the damaged myocardium post myocardial infarction to prevent comorbidities such as heart failure.

Scope
- Overview of ACS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized ACS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ACS therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global ACS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global ACS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ACS therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global ACS therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2016

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on